{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:44:04Z","timestamp":1782805444385,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate real-world efficacy, durability, and safety of faricimab in treatment-na\u00efve Asian patients with neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of treatment-na\u00efve nAMD eyes treated with faricimab at a single centre in South Korea. After four monthly loading doses, treatment intervals (Q8W, Q12W, Q16W) were assigned based on disease activity at weeks 20 and 24. Comprehensive assessments included best-corrected visual acuity (BCVA), central subfield thickness (CST), pigment epithelial detachment (PED) height, subfoveal choroidal thickness (SFCT), and intraretinal\/subretinal fluid (IRF\/SRF) presence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-eight treatment-na\u00efve eyes were included. Mean age was 72.8 (9.0) years. At week 20, BCVA improved from 62.1 (15.4) to 69.3 (14.6) ETDRS letters (+\u20097.1 letters,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). CST decreased from 414 (150) to 280 (94) \u00b5m (\u2212\u2009134\u00a0\u03bcm,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). PED height decreased from 297 (167) to 171 (116) \u00b5m (\u2212\u200943%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). SFCT decreased from 208 (91) to 184 (83) \u00b5m (\u2212\u200912%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with PCV eyes showing the greatest reduction (\u2212\u200932\u00a0\u03bcm,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). IRF presence (1\u00a0mm\/6\u00a0mm) decreased from 33%\/34% to 7%\/9%, and SRF from 78%\/84% to 12%\/20% at week 20. At week 60, 52.3% achieved Q16W and 67.0% achieved \u2265Q12W intervals. Among 168 eyes in the safety analysis, there was 1 case of mild vitritis and 2 cases of RPE tear, with no cases of endophthalmitis or retinal vasculitis reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initiation of faricimab in treatment-na\u00efve nAMD patients resulted in favourable visual and anatomical outcomes with durable treatment intervals and a low incidence of adverse events in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05019-w","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:14:14Z","timestamp":1781172854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"26","author":[{"given":"Woohyok","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsik","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"5019_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u2013116.","journal-title":"Lancet Glob Health"},{"key":"5019_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicentre cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"5019_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"5019_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19\u201330.","journal-title":"Ophthalmol Retina"},{"key":"5019_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimised for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388.","journal-title":"EMBO Mol Med"},{"key":"5019_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomised trial. Ophthalmology. 2019;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"5019_CR7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Holz FG, Guymer R, Torres RS, Paris LP. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35:1305\u201316.","journal-title":"Eye (Lond)"},{"key":"5019_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"5019_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"},{"key":"5019_CR10","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","volume":"261","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Cheung CMG, Iida T, et al. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023;261:3125\u201337.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5019_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","volume":"132","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Lim JI, Priglinger S, et al. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA\/LUCERNE Trials in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2025;132:519\u201326.","journal-title":"Ophthalmology"},{"key":"5019_CR12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/IAE.0000000000004087","volume":"44","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Brown DM, Engstrom RE, et al. Retinal fluid dynamics and treatment outcomes with faricimab: post hoc analysis of TENAYA\/LUCERNE. Retina. 2024;44:456\u201365.","journal-title":"Retina"},{"key":"5019_CR13","first-page":"112","volume":"259","author":"GJ Jaffe","year":"2024","unstructured":"Jaffe GJ, Westby K, Csaky KG, et al. Anatomical and visual outcomes to faricimab in eyes with persistent fluid despite prior anti-VEGF therapy: post hoc analysis from TENAYA\/LUCERNE. Am J Ophthalmol. 2024;259:112\u201321.","journal-title":"Am J Ophthalmol"},{"key":"5019_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018;125:708\u201324.","journal-title":"Ophthalmology"},{"key":"5019_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina"},{"key":"5019_CR16","first-page":"1069","volume":"5","author":"KYC Teo","year":"2021","unstructured":"Teo KYC, Gillies M, Fraser-Bell S. Angiopoietin-2 in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmol Retina. 2021;5:1069\u201377.","journal-title":"Ophthalmol Retina"},{"key":"5019_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:14\u201333.","journal-title":"Eye (Lond)"},{"key":"5019_CR18","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye (Lond). 2023;37:3574\u201381.","journal-title":"Eye (Lond)"},{"key":"5019_CR19","first-page":"1423","volume":"262","author":"C Framme","year":"2024","unstructured":"Framme C, Eter N, Hamacher T, et al. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration in Germany. Graefes Arch Clin Exp Ophthalmol. 2024;262:1423\u201332.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5019_CR20","first-page":"1678","volume":"38","author":"S Sivaprasad","year":"2024","unstructured":"Sivaprasad S, Oyetunde S, Engstrom RE, et al. Real-world visual outcomes with faricimab for neovascular age-related macular degeneration: UK experience. Eye (Lond). 2024;38:1678\u201385.","journal-title":"Eye (Lond)"},{"key":"5019_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bhimavarapu A, Romero RE, Nah MD, Yee KMP. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"5019_CR22","first-page":"627","volume":"14","author":"F Gomi","year":"2025","unstructured":"Gomi F, Staurenghi G, Holz FG, Guymer R, Kim JE, Korobelnik JF, Lai TYY, Sadda SR. To treat or not to treat? Resolving the question of subretinal and intraretinal fluid in age-related macular degeneration: a narrative review. Ophthalmol Ther. 2025;14:627\u201351.","journal-title":"Ophthalmol Ther"},{"key":"5019_CR23","doi-asserted-by":"publisher","first-page":"e001855","DOI":"10.1136\/bmjophth-2024-001855","volume":"9","author":"P Shah","year":"2024","unstructured":"Shah P, Rafijah N, Tang Y, Engstrom RE, Khanani AM. Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD). BMJ Open Ophthalmol. 2024;9:e001855.","journal-title":"BMJ Open Ophthalmol"},{"key":"5019_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F, Koizumi H, Tsujikawa A, Okada AA, Iwasaki K, Ochi H. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023;67:301\u201310.","journal-title":"Jpn J Ophthalmol"},{"key":"5019_CR25","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00417-022-05586-w","volume":"260","author":"KB Freund","year":"2022","unstructured":"Freund KB, Staurenghi G, Jung JJ, et al. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. Graefes Arch Clin Exp Ophthalmol. 2022;260:2437\u201347.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5019_CR26","first-page":"349","volume":"8","author":"SJ Talks","year":"2024","unstructured":"Talks SJ, Sheridan CM, Garcia-Arumi J, et al. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration. Ophthalmol Retina. 2024;8:349\u201358.","journal-title":"Ophthalmol Retina"},{"key":"5019_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40662-022-00287-1","volume":"9","author":"Y Tong","year":"2022","unstructured":"Tong Y, Zhang Z, Wang J, et al. Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography. Eye Vis (Lond). 2022;9:16.","journal-title":"Eye Vis (Lond)"},{"key":"5019_CR28","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, Korobelnik JF, Sadda SR, Staurenghi G, Guymer R, Giani A. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond). 2023;37:1758\u201365.","journal-title":"Eye (Lond)"},{"key":"5019_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/IAE.0000000000002786","volume":"41","author":"S Rezar-Dreindl","year":"2021","unstructured":"Rezar-Dreindl S, Eibenberger K, Buehl W, et al. Clinical outcomes of different subtypes of neovascular age-related macular degeneration during aflibercept treatment. Retina. 2021;41:103\u201310.","journal-title":"Retina"},{"key":"5019_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020;127:1345\u201359.","journal-title":"Ophthalmology"},{"key":"5019_CR31","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","volume":"18","author":"SJ Haug","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680.","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05019-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05019-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05019-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:48:03Z","timestamp":1782802083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05019-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5019"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05019-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki. The study was reviewed by the Public Institutional Review Board (Public IRB) designated by the Ministry of Health and Welfare of South Korea and operated by the Korea National Institute for Bioethics Policy (approval number: P01-202510-01-057; date: 20 January 2026), which granted an exemption from full ethical review in accordance with Article 13 of the Enforcement Rules of the Bioethics and Safety Act of South Korea, given the retrospective nature of the study using de-identified medical records. The need for informed consent was waived by the same committee for the same reason.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WC is a consultant for Bayer and Roche. This study was financially supported by Roche. The sponsor had no role in the design, conduct, analysis, interpretation of data, or reporting of this study. JK, JJ, and SP declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}